Protocol Ledger

NCT07687056 · Phase III · RECRUITING

ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

Interventional Phase III clinical trial protocol NCT07687056 sponsored by University of Calgary in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-11 Enrollment: 1,500 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07687056
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,500 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07687056
Protocol FieldVerified Registry Value
NCT IdentifierNCT07687056
Consolidated Lead SponsorUniversity of Calgary
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,500 participants (ESTIMATED)
Registered Start Date2026-08-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07687056
Hospital Research SiteLocationSite Profile
University of AlbertaEdmonton, CanadaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI